Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGI-0301 plus nivolumab in advanced hepatocellular carcinoma and renal cell carcinoma
CTR20261875Phase 2Active
- Sponsor
- Haichang Biotech
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of WGI-0301, nivolumab in hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), sponsored by Haichang Biotech. Started Jun 2026; status: active.
02
Drugs
WGI-0301nivolumab
03
Conditions
hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20261875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261875.